Psychedelics News

Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy Adults

This exploratory preprint analysed music responses from a double-blind, placebo-controlled psilocybin crossover trial (0.26 mg/kg). Part 1 (n=19) screened eight compositions; Part 2 (n=17) compared emotional responses...

FDA Holds Historic Public Hearing on Psychedelic Therapies

A highly anticipated public hearing at the FDA focused on questions about credentialing providers of psychedelic-assisted therapies, patient safety, data standardization, and equitable access to emerging therapies. Th...

Psilocybin may help the brain recover from concussion, new study shows

Psilocybin could be an unexpected avenue for treating an injury that currently has few options beyond rest and symptom management.

Weekly Psychedelic Policy Briefing, September 21, 2026

The FDA heard 80 speakers on the future of psychedelic drugs, and its federal panel asked none of them a question. The American Legion endorsed a VA bill in terms its text doesn't support, and Alabama showed how one s...

N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state

This secondary analysis of a double-blind, randomised, placebo-controlled EEG study (n=25) found that an intranasal DMT and buccal harmine formulation produced faster, shorter-lasting brain activity states than harmin...

N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state

This secondary analysis of a double-blind, randomised, placebo-controlled EEG study (n=25) found that an intranasal DMT and buccal harmine formulation produced faster, shorter-lasting brain activity states than harmin...

Did psychedelics help build ancient civilizations?: 5 Questions for journalist Andrew Lawler

Lawler discusses new archeological tools for studying psychoactive plant residues.

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

Introducing The Psychedelic News Feed Podcast

Psychedelic Therapy Is Imminent. Will the FDA Get It Right?

PLUS art installations at Burning Man, plant medicine in Africa, and bioluminescent mushrooms. [...] Read More...

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression

In an open-label, single-arm dose-escalation pilot (n=14) of psilocybin-assisted therapy for bipolar II depression, psilocybin (10 mg, with 25 mg if needed) was generally well tolerated and produced significant, susta...

A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults

This Phase 1 randomized, double-blind, placebo-controlled study tested single oral psilocybin doses of 0.5–4.0 mg in 56 healthy adults. There were no serious adverse events or cognitive decrements. Subjective effects ...

Sensorium Therapeutics reported Phase 1a data showing that a single 3 mg dose of SNTX-2643 produced CNS activity within two hours and attenuated stress responses at two and 24 hours in healthy adults.

In 63 healthy adults, SNTX-2643 was generally well tolerated and showed predictable pharmacokinetics with no clinically significant food effect. In a 25-person target-engagement cohort, the 3 mg dose reduced brain res...

A longitudinal analysis of the clinical practice of ketamine assisted psychotherapy with adolescents and young adults

This longitudinal observational study (n=19) examined ketamine-assisted psychotherapy in adolescents and young adults aged 14–24 with varied emotional and relationship difficulties. Depression scores fell over repeate...

HMNC Brain Health has appointed Dr Maximilian Doebler as CEO, effective immediately, as it advances late-stage programmes for difficult-to-treat depression.

Doebler joined HMNC in 2019 and has served as Managing Director and Chief Business Officer since 2022. He has overseen development of Ketabon, an oral prolonged-release ketamine formulation for treatment-resistant dep...